Medicine and Dentistry
T Cell
100%
Radiation Therapy
83%
Chimeric Antigen Receptor T-Cell
69%
Neoplasm
65%
Immunotherapy
47%
Patient
43%
B-Cell Lymphoma
36%
Therapeutic Procedure
30%
Chimeric Antigen Receptor
30%
Lymphoma
30%
Chemotherapy
27%
Toll Like Receptor 7
25%
Host
25%
Cytotoxic T-Cell
24%
Non-Hodgkin Lymphoma
23%
Lymphocyte
23%
Cytokine
23%
Receptor
22%
Ovarian Cancer
22%
Oropharyngeal Cancer
22%
Immune Response
21%
Immunoglobulin
19%
Cells
16%
Solid Malignant Neoplasm
15%
Antigen
15%
Cell Therapy
15%
Enalapril Maleate
15%
Agonist
14%
Laboratory
14%
Cell Population
14%
B Cell
13%
Overall Survival
13%
Colorectal Cancer
12%
Malignant Neoplasm
12%
Tumor Model
12%
Tumor Microenvironment
12%
Protein
12%
Carcinoembryonic Antigen
12%
Tumor Immunity
11%
Tumor Antigen
11%
Obinutuzumab
11%
Hexametaphosphate Sodium
11%
Tumor Infiltrating Lymphocyte
11%
Eotaxin 2
11%
T-Helper Cell
11%
Ligation
11%
Cell Activation
11%
Natural Killer Cell
11%
Chemokine
11%
Cellular Imaging
11%
Immunology and Microbiology
Immunotherapy
49%
Dendritic Cell
38%
B Cell
38%
Immunity
33%
CD19
30%
Electric Potential
29%
Cells
26%
Antigen
25%
Agonist
25%
Chimeric Antigen Receptor T-Cell
25%
Radiation
24%
Immune Response
23%
Chimeric Antigen Receptor
22%
Mouse
20%
Intravenous Immunoglobulin
19%
Comprehension
19%
Carcinoembryonic Antigen
16%
CD4
16%
Host
15%
Monoclonal Antibodies
15%
Cell Population
15%
T-Helper Cell
14%
CD20
14%
Obinutuzumab
13%
Cell Death
12%
Antineoplastic Activity
12%
Antigen Presentation
12%
Monospecific Antibody
12%
Natural Killer Cell
12%
Engraftment
12%
Immune Receptor
12%
Species
12%
CD19 Antigen
12%
Tumor Immunity
11%
Eotaxin 2
11%
Escherichia coli
11%
Cytotoxic T-Cell
11%
Lymphoma Cell
11%
Cancer Immunotherapy
11%
Mycobacterium bovis
11%
Solid
11%
CD2
11%
MHC Class I
11%
Escherichia Coli Vaccine
11%
Interleukin 12
11%
Cell Activity
11%
Cell Activation
11%
Cancer Antibody
11%
Major Histocompatibility Complex
11%
Leukemia Cell
11%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
60%
Malignant Neoplasm
37%
Immunotherapy
34%
Antibody
26%
Immunoglobulin
26%
Obinutuzumab
25%
Chimeric Antigen Receptor
24%
Cell Death
23%
Programmed Death-Ligand 1
18%
Biological Marker
17%
Clinical Trial
16%
Rituximab
15%
Agonist
14%
Antigen
14%
Lymphoma
14%
Rituximab
14%
Actin
13%
Protein
12%
Radiation
12%
Solid Malignant Neoplasm
12%
Programmed Cell Death
12%
Tumor Model
12%
Reactive Oxygen Metabolite
11%
Escherichia coli
11%
Programmed Death 1 Receptor
11%
Toll Like Receptor 7
11%
Carcinoembryonic Antigen
11%
Leukemia
11%
Oropharynx Cancer
11%
Escherichia Coli Vaccine
11%
Nonhodgkin Lymphoma
11%
Clinical Study
11%
Melanoma
9%
Cytotoxic T Lymphocyte Antigen 4
9%
Listeriolysin O
9%
Mouse
9%
Monoclonal Antibody
8%
Vaccine
7%
Toxicity
7%
B Cell Lymphoma
6%
Combination Therapy
6%
Chronic Lymphatic Leukemia
5%
Kidney Cancer
5%